BSE: 538837
Jeevan Scientific Technology L
Runs clinical research and bioanalytical work for pharmaceutical clients from facilities in Hyderabad. The core business is Clinical Research Services, which contributed 79.3% of segment revenue at Rs 58.42 crore with EBIT of Rs 15.27 crore, covering Bioavailability/Bioequivalence (BA/BE) studies, clinical pharmacology trials, and bioanalytical work. CDSCO has approved expanding the Hyderabad BA/BE centre beds from 132 regular and 6 ICU beds to 156 regular and 8 ICU beds, and the USFDA inspected the Manikonda bioanalytical facility in July 2026 with zero 483 observations. An Information Technology Services line contributed 15.3% of segment revenue at Rs 11.25 crore but was loss-making at the EBIT level. A Profit on Sale of Investments stream added another 5.5% of segment revenue. Employee costs are the largest expense at 35.2% of revenue, followed by other operating expenses at 41.0% and depreciation at 10.8%. FY26 consolidated revenue was Rs 61.54 crore with net profit of Rs 1.03 crore. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Clinical Research Services (79%), Information Technology Service (15%), Profit on Sale of Investments (6%). Service-oriented, staff-heavy healthcare research and analytics
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 68 | 36 | 40 | 47 | 62 |
| EBITDA (ex other income) | 17 | 1 | 5 | 7 | 10 |
| margin % | 24.7 | 3.6 | 11.6 | 15.8 | 15.9 |
| Owners' profit | 12 | (3) | 0 | 0 | 1 |
| EPS, as reported (₹) | 7.94 | (2.00) | (0.86) | 0.04 | 0.52 |
| ROE % · ROCE % | 23.6 · 34.2 | (6.3) · (5.0) | (2.7) · (1.1) | 0.1 · 2.7 | 1.4 · 4.8 |
| Debt / equity (x) | 0.19 | 0.13 | 0.22 | 0.30 | 0.24 |
| Cash from operations | — | (9) | 3 | 10 | 0 |
| Capex | — | (8) | 0 | (16) | (8) |
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 13 | 11 | 13 | 10 | 9 | 12 | 19 | 21 |
| Profit before tax | 1 | 1 | 0 | (3) | (4) | 0 | 3 | 3 |
| Net profit | 1 | 0 | 0 | (1) | (3) | 0 | 2 | 2 |
| EPS (₹) | 0.66 | 0.16 | 0.03 | (0.81) | (2.03) | 0.01 | 1.52 | 0.92 |
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| Jeevan Scientific Technology L ◆ | 165 | 196.9 | 2.26 | 16.0 | 1.4 | 2.4 | 5.1 | 21.5 |
| NOVELIX PHARMACEUTICALS LIMITE | 160 | — | 21.54 | — | (3.3) | (3.3) | — | (9.5) |
| GlobalSpace Technologies Limit | 127 | 41.5 | 2.23 | 27.6 | 5.0 | 3.4 | 13.7 | 7.1 |
| Adeshwar Meditex Limited | 23 | 21.7 | — | — | — | — | — | — |
| Vanta Bioscience Limited | 15 | 3.3 | — | — | — | 0.0 | (29.0) | — |
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 196.9 | 37.2 | 59 of 63 | 7% |
| P/B | 2.3 | 5.2 | 20 of 57 | 66% |
| ROCE | 2.4 | 8.0 | 50 of 69 | 28% |
| ROE | 1.4 | 9.1 | 45 of 57 | 21% |
| Debt / Equity | 0.2 | 0.1 | 34 of 56 | 40% |
| EBITDA margin | 21.5 | 21.5 | 29 of 57 | 50% |
| Revenue growth | 111.6 | 20.2 | 4 of 57 | 95% |
| Profit growth | 245.9 | 11.4 | 3 of 55 | 96% |
| Market cap | 165 | 244 | 41 of 71 | 43% |
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 1 Oct 2026 · US FDA closes Jeevan Scientific inspection with Zero 483 observations | regulatory legal | high | — | — |
| 29 Sept 2026 · Closure of trading window under SEBI (Prohibition of Insider Trading) Regulations, 2015. | compliance | minimal | — | — |
| 25 Sept 2026 · 28th AGM results: all 8 resolutions passed with wide majority | board shareholder meetings | medium | — | — |
| 25 Sept 2026 · 28th AGM outcome: All 8 resolutions passed with near-unanimous support | board shareholder meetings | low | — | — |
| 4 Sept 2026 · Notice of 28th AGM, book closure and e-voting information | compliance | minimal | — | — |
| 3 Sept 2026 · Jeevan Scientific Technology submits 28th Annual Report for FY26 | compliance | medium | — | — |
| 3 Sept 2026 · 28th AGM on Sep 25, 2026; revenue and profit up, director changes proposed | compliance | minimal | — | — |
| 13 Aug 2026 · No deviation in preferential allotment funds for June 2026 quarter | compliance | minimal | — | — |
| 13 Aug 2026 · Board Meeting Outcome: Director Re-appointments and Q1 FY27 Results | management changes | high | — | — |
| 13 Aug 2026 · Q1 FY27 results revenue doubles PAT turnaround board changes | management changes | medium | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.